<DOC>
	<DOCNO>NCT01946711</DOCNO>
	<brief_summary>The study create data selection clinically relevant primary endpoint ass efficacy safety Buparid/PARI SINUS compare Budes Nasal Spray therapy chronic rhinosinusitis ( CRS ) polyposis nasi adult patient . Ideally , select parameter allow correlation objective methodology clinical outcome study patient .</brief_summary>
	<brief_title>Buparid/PARI SINUS Versus BudesÂ® Nasal Spray Therapy Chronic Rhinosinusitis With Polyposis Nasi</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patient confirm diagnosis chronic rhinosinusitis ( CRS ) polyposis nasi grade IIII Patient PNIF &gt; 7 l/min separate leave right side nose Patient 's write informed consent Male female , &gt; = 18 year age Patient able undergo nasal therapy without restriction Capable understanding purpose risk clinical trial Female patient childbearing potential must negative urine pregnancy test prior first IMP administration Patient complete correctly diary Washin Phase Patients cystic fibrosis Patients polyposis nasi grade IV Patients prior sinonasal surgery ( exemption : polypectomy ) Patients primary ciliaritis Pregnant breastfeed woman Patients suspect active upper airway infection Receipt investigational drug part clinical trial within 4 week prior first administration IMP Drug alcohol abuse Endstage malignancy Known hypersensitivity Budesonide Patients oral steroid therapy within last 4 week Patients frequent epistaxis ( &gt; 2 per month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CRS</keyword>
	<keyword>polyposis</keyword>
</DOC>